LGND Ligand Pharmaceuticals Incorporated

Ligand to Participate in Two Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:

  • 14th Annual Craig-Hallum Institutional Investor Conference in Minneapolis. Conference takes place on Wednesday, May 31, 2017 with one-on-one meetings only. John Higgins, CEO; Matt Foehr, President and COO; and Matt Korenberg, CFO, will attend for Ligand.
  • Jefferies Healthcare Conference in New York City. Presentation takes place on Thursday, June 8, 2017 at 4:00 p.m. Eastern time (1:00 p.m. Pacific time). John Higgins, CEO; Matt Foehr, President and COO; and Matt Korenberg, CFO, will attend for Ligand.

A live webcast of the presentation will be available on Ligand’s website at www.ligand.com. A replay of the presentation will be archived on the website for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.

Follow Ligand on Twitter @Ligand_LGND.

EN
22/05/2017

Underlying

LGNDLigand Pharmaceuticals Incorporated

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ligand Pharmaceuticals Incorporated

Free Trial
LGND Ligand Pharmace...

Ligand Pharmaceuticals Inc: 1 director

A director at Ligand Pharmaceuticals Inc sold 10,000 shares at 170.809USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

LGND LIGAND PHARMACEUTICALS INCORPORATED
09/24/25 September 24, 2025 1 EN
 PRESS RELEASE
Free
LGND Ligand Pharmace...

Ligand to Participate in September Investor Conferences

Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand ma...

August 19, 2025 1 EN
 PRESS RELEASE
Free
LGND Ligand Pharmace...

Ligand Announces Closing of Convertible Senior Notes Offering

Ligand Announces Closing of Convertible Senior Notes Offering JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible senior notes due 2030 (the “notes”). The aggregate principal amount of the notes sold in the offering was $460.0 million, which includes the purchase of an additional $60.0 million aggregate principal amount of notes by the initial purchasers pursuant to the full exercise of the initial purchasers’ option to purcha...

August 14, 2025 1 EN
 PRESS RELEASE
Free
LGND Ligand Pharmace...

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offe...

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ligand also granted the initial purchasers of the notes (the “initial purchasers...

August 12, 2025 1 EN
 PRESS RELEASE
Free
LGND Ligand Pharmace...

Ligand Announces Proposed Offering of $400 Million of Convertible Seni...

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors. Ligand also expec...

August 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch